The biomarker and therapeutic potential of miRNA in Alzheimer's disease.

Alzheimer's disease (AD) is the most common cause of dementia. Currently, a clinical diagnosis of AD is based on evidence of both cognitive and functional decline. Progression is monitored by detailed clinical evaluations over many months to years. It is increasingly clear that to advance disease-modifying therapies for AD, patients must be identified and treated early, before obvious cognitive and functional changes. In addition, better methods are needed to sensitively monitor progression of disease and therapeutic efficacy. Therefore, considerable research has focused on characterizing biomarkers that can identify the disease early as well as accurately monitor disease progression. miRNA offer a unique opportunity for biomarker development. Here, we review research focused on characterizing miRNA as potential biomarkers and as a treatment for disease.

[1]  C. Wahlestedt,et al.  Knockdown of BACE1-AS Nonprotein-Coding Transcript Modulates Beta-Amyloid-Related Hippocampal Neurogenesis , 2011, International journal of Alzheimer's disease.

[2]  G. Ruvkun,et al.  Posttranscriptional regulation of the heterochronic gene lin-14 by lin-4 mediates temporal pattern formation in C. elegans , 1993, Cell.

[3]  Brian D Athey,et al.  New class of microRNA targets containing simultaneous 5'-UTR and 3'-UTR interaction sites. , 2009, Genome research.

[4]  M. C. Butler,et al.  Relieving bottlenecks in RNA drug discovery for retinal diseases. , 2012, Advances in experimental medicine and biology.

[5]  Evan T. Geller,et al.  Antisense-mediated Exon Skipping Decreases Tau Protein Expression: A Potential Therapy for Tauopathies , 2014, Molecular therapy. Nucleic acids.

[6]  S. M. Robinson,et al.  Testing the neurovascular hypothesis of Alzheimer's disease: LRP-1 antisense reduces blood-brain barrier clearance, increases brain levels of amyloid-beta protein, and impairs cognition. , 2009, Journal of Alzheimer's disease : JAD.

[7]  T. Tuschl,et al.  Human Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. , 2004, Molecular cell.

[8]  A. Cesarani,et al.  A novel mutation within the MIR96 gene causes non-syndromic inherited hearing loss in an Italian family by altering pre-miRNA processing , 2011, Human molecular genetics.

[9]  V. Ambros,et al.  The lin-4 regulatory RNA controls developmental timing in Caenorhabditis elegans by blocking LIN-14 protein synthesis after the initiation of translation. , 1999, Developmental biology.

[10]  Peter T. Nelson,et al.  Patterns of microRNA expression in normal and early Alzheimer’s disease human temporal cortex: white matter versus gray matter , 2011, Acta Neuropathologica.

[11]  Nan Hu,et al.  Circulating miR-125b as a biomarker of Alzheimer's disease , 2014, Journal of the Neurological Sciences.

[12]  M. Strong,et al.  Altered microRNA expression profile in amyotrophic lateral sclerosis: a role in the regulation of NFL mRNA levels , 2013, Molecular Brain.

[13]  M. Fivaz,et al.  High-content imaging of presynaptic assembly , 2014, Front. Cell. Neurosci..

[14]  W. Banks,et al.  Central and peripheral administration of antisense oligonucleotide targeting amyloid-β protein precursor improves learning and memory and reduces neuroinflammatory cytokines in Tg2576 (AβPPswe) mice. , 2014, Journal of Alzheimer's disease : JAD.

[15]  Karen S. Frese,et al.  Multivariate miRNA signatures as biomarkers for non-ischaemic systolic heart failure. , 2013, European heart journal.

[16]  Xiaowei Xu,et al.  MicroRNA isolation from formalin-fixed, paraffin-embedded tissues. , 2011, Methods in molecular biology.

[17]  C. Croce,et al.  Frequent deletions and down-regulation of micro- RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Phillip A Sharp,et al.  MicroRNA sponges: progress and possibilities. , 2010, RNA.

[19]  V. Ambros,et al.  The C. elegans heterochronic gene lin-4 encodes small RNAs with antisense complementarity to lin-14 , 1993, Cell.

[20]  Muller Fabbri,et al.  A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. , 2005, The New England journal of medicine.

[21]  Guiliang Tang,et al.  The Expression of MicroRNA miR-107 Decreases Early in Alzheimer's Disease and May Accelerate Disease Progression through Regulation of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 , 2008, The Journal of Neuroscience.

[22]  K. Blennow,et al.  Reduced expression of hsa-miR-27a-3p in CSF of patients with Alzheimer disease , 2013, Neurology.

[23]  Hyman M. Schipper,et al.  MicroRNA Expression in Alzheimer Blood Mononuclear Cells , 2007, Gene regulation and systems biology.

[24]  A. Roses,et al.  Identification of miRNA Changes in Alzheimer's Disease Brain and CSF Yields Putative Biomarkers and Insights into Disease Pathways , 2008 .

[25]  R. Shiekhattar,et al.  Human RISC Couples MicroRNA Biogenesis and Posttranscriptional Gene Silencing , 2005, Cell.

[26]  Peter T Nelson,et al.  A study of small RNAs from cerebral neocortex of pathology-verified Alzheimer's disease, dementia with lewy bodies, hippocampal sclerosis, frontotemporal lobar dementia, and non-demented human controls. , 2013, Journal of Alzheimer's disease : JAD.

[27]  B. Ray,et al.  MicroRNA-339-5p Down-regulates Protein Expression of β-Site Amyloid Precursor Protein-Cleaving Enzyme 1 (BACE1) in Human Primary Brain Cultures and Is Reduced in Brain Tissue Specimens of Alzheimer Disease Subjects* , 2013, The Journal of Biological Chemistry.

[28]  Martin Chalfie,et al.  Mutations that lead to reiterations in the cell lineages of C. elegans , 1981, Cell.

[29]  Patrick Callier,et al.  Germline deletion of the miR-1792 cluster causes growth and skeletal defects in humans , 2011 .

[30]  B. Davidson,et al.  RNA polymerase III transcribes human microRNAs , 2006, Nature Structural &Molecular Biology.

[31]  P. Fasanaro,et al.  MicroRNA Dysregulation in Diabetic Ischemic Heart Failure Patients , 2012, Diabetes.

[32]  S. Srikantan,et al.  Paradoxical microRNAs , 2011, Cell cycle.

[33]  V. Ambros,et al.  Circulating Cell and Plasma microRNA Profiles Differ between Non-ST-Segment and ST-Segment-Elevation Myocardial Infarction , 2013, Family medicine & medical science research.

[34]  M. Capogrossi,et al.  Diagnostic Potential of Plasmatic MicroRNA Signatures in Stable and Unstable Angina , 2013, PloS one.

[35]  D. Holtzman,et al.  Neuronal Clearance of Amyloid-β by Endocytic Receptor LRP1 , 2013, The Journal of Neuroscience.

[36]  Te Liu,et al.  Attenuated ability of BACE1 to cleave the amyloid precursor protein via silencing long noncoding RNA BACE1-AS expression , 2014, Molecular medicine reports.

[37]  Sanghyuk Lee,et al.  MicroRNA genes are transcribed by RNA polymerase II , 2004, The EMBO journal.

[38]  P. Mitchell,et al.  Mutational analysis of MIR184 in sporadic keratoconus and myopia. , 2013, Investigative ophthalmology & visual science.

[39]  A. Pestronk,et al.  An antisense oligonucleotide against SOD1 delivered intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, randomised, first-in-man study , 2013, The Lancet Neurology.

[40]  Xiutang Cao,et al.  Analysis of circulating microRNA biomarkers for breast cancer detection: a meta-analysis , 2014, Tumor Biology.

[41]  B. De Felice,et al.  A miRNA signature in leukocytes from sporadic amyotrophic lateral sclerosis. , 2012, Gene.

[42]  W. Banks,et al.  Peripheral administration of antisense oligonucleotides targeting the amyloid-β protein precursor reverses AβPP and LRP-1 overexpression in the aged SAMP8 mouse brain. , 2012, Journal of Alzheimer's disease : JAD.

[43]  G. Yousef,et al.  Clinical evaluation of microRNA expression profiling in non small cell lung cancer. , 2013, Lung cancer.

[44]  Lilius Hg,et al.  Meta-analysis of the differentially expressed colorectal cancer-related microRNA expression profiles. , 2014 .

[45]  J. Cheng,et al.  High resolution of microRNA signatures in human whole saliva. , 2011, Archives of oral biology.

[46]  Peer Bork,et al.  Target-specific requirements for enhancers of decapping in miRNA-mediated gene silencing. , 2007, Genes & development.

[47]  R. Shiekhattar,et al.  TRBP recruits the Dicer complex to Ago2 for microRNA processing and gene silencing , 2005, Nature.

[48]  Y. Kawahara,et al.  TDP-43 promotes microRNA biogenesis as a component of the Drosha and Dicer complexes , 2012, Proceedings of the National Academy of Sciences.

[49]  J. Borén,et al.  [Homozygous familial hypercholesterolaemia: new insights and guidance for clinicians to improve detection and clinical management. A position paper from the Consensus Panel on Familial Hypercholesterolaemia of the European Atherosclerosis Society]. , 2015, Turk Kardiyoloji Dernegi arsivi : Turk Kardiyoloji Derneginin yayin organidir.

[50]  J. Schneider,et al.  National Institute on Aging–Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease , 2012, Alzheimer's & Dementia.

[51]  Ana Kozomara,et al.  miRBase: annotating high confidence microRNAs using deep sequencing data , 2013, Nucleic Acids Res..

[52]  I. Grundke‐Iqbal,et al.  Abnormal hyperphosphorylation of tau: sites, regulation, and molecular mechanism of neurofibrillary degeneration. , 2012, Journal of Alzheimer's disease : JAD.

[53]  Kazuhiko Hayashi,et al.  Systematic analysis of microRNA expression of RNA extracted from fresh frozen and formalin-fixed paraffin-embedded samples. , 2007, RNA.

[54]  R. Margis,et al.  Identification of blood microRNAs associated to Parkinsonĭs disease. , 2011, Journal of biotechnology.

[55]  A. Russell,et al.  Disruption of skeletal muscle mitochondrial network genes and miRNAs in amyotrophic lateral sclerosis , 2013, Neurobiology of Disease.

[56]  Yuejin Yang,et al.  Mipomersen is a Promising Therapy in the Management of Hypercholesterolemia: A Meta-Analysis of Randomized Controlled Trials , 2014, American Journal of Cardiovascular Drugs.

[57]  Thomas J. Montine,et al.  MicroRNA in Alzheimer’s disease: an exploratory study in brain, cerebrospinal fluid and plasma , 2013, Biomarkers : biochemical indicators of exposure, response, and susceptibility to chemicals.

[58]  W. Schmiegel,et al.  MicroRNAs in cerebrospinal fluid as biomarker for disease course monitoring in primary central nervous system lymphoma , 2012, Journal of Neuro-Oncology.

[59]  Murray Grossman,et al.  TARDBP mutations in amyotrophic lateral sclerosis with TDP-43 neuropathology: a genetic and histopathological analysis , 2008, The Lancet Neurology.

[60]  Zoltan Dezso,et al.  Circulating miRNA Biomarkers for Alzheimer's Disease , 2013, Alzheimer's & Dementia.

[61]  Tamas Dalmay,et al.  Mutations in the seed region of human miR-96 are responsible for nonsyndromic progressive hearing loss , 2009, Nature Genetics.

[62]  D. Butterfield,et al.  Antisense oligonucleotide against GSK-3β in brain of SAMP8 mice improves learning and memory and decreases oxidative stress: Involvement of transcription factor Nrf2 and implications for Alzheimer disease. , 2014, Free radical biology & medicine.

[63]  S. Khoo,et al.  Plasma-based circulating MicroRNA biomarkers for Parkinson's disease. , 2012, Journal of Parkinson's disease.

[64]  Xing-mei Zhang,et al.  Antisense inhibition of acetylcholinesterase gene expression for treating cognition deficit in Alzheimer's disease model mice , 2005, Brain Research.

[65]  Haifeng Jin,et al.  MicroRNAs as Potential Biomarkers for Diagnosing Cancers of Central Nervous System: a Meta-analysis , 2014, Molecular Neurobiology.

[66]  B. Cullen,et al.  Exportin-5 mediates the nuclear export of pre-microRNAs and short hairpin RNAs. , 2003, Genes & development.

[67]  D. Butterfield,et al.  Antisense directed against PS-1 gene decreases brain oxidative markers in aged senescence accelerated mice (SAMP8) and reverses learning and memory impairment: a proteomics study. , 2013, Free radical biology & medicine.

[68]  Nancy M Bonini,et al.  MicroRNAs and neurodegeneration: role and impact. , 2013, Trends in cell biology.

[69]  Jessica A. Weber,et al.  The microRNA spectrum in 12 body fluids. , 2010, Clinical chemistry.

[70]  Kyle Kai-How Farh,et al.  Expanding the microRNA targeting code: functional sites with centered pairing. , 2010, Molecular cell.

[71]  M. Garcia-Blanco,et al.  Correction of tau mis-splicing caused by FTDP-17 MAPT mutations by spliceosome-mediated RNA trans-splicing , 2009, Human molecular genetics.

[72]  K. Tan,et al.  Blood microRNAs in Low or No Risk Ischemic Stroke Patients , 2013, International journal of molecular sciences.

[73]  D. Bartel.  MicroRNAs: Target Recognition and Regulatory Functions , 2009, Cell.

[74]  L. Pang,et al.  The MicroRNAs as Prognostic Biomarkers for Survival in Esophageal Cancer: A Meta-Analysis , 2014, TheScientificWorldJournal.

[75]  J. Prehn,et al.  Increased Expression of MicroRNA-29a in ALS Mice: Functional Analysis of Its Inhibition , 2014, Journal of Molecular Neuroscience.

[76]  D. Haber,et al.  Dual Role for Argonautes in MicroRNA Processing and Posttranscriptional Regulation of MicroRNA Expression , 2007, Cell.

[77]  W. Guan,et al.  Identification of Circulating MicroRNAs as Novel Potential Biomarkers for Gastric Cancer Detection: A Systematic Review and Meta-Analysis , 2014, Digestive Diseases and Sciences.

[78]  T. Skaar,et al.  Incubation of Whole Blood at Room Temperature Does Not Alter the Plasma Concentrations of MicroRNA-16 and -223 , 2013, Drug Metabolism and Disposition.

[79]  W. Lukiw,et al.  Micro-RNA speciation in fetal, adult and Alzheimer's disease hippocampus , 2007, Neuroreport.

[80]  H. Nonogi,et al.  Assessment of plasma miRNAs in congestive heart failure. , 2011, Circulation journal : official journal of the Japanese Circulation Society.

[81]  W. Lukiw,et al.  microRNA (miRNA) speciation in Alzheimer's disease (AD) cerebrospinal fluid (CSF) and extracellular fluid (ECF). , 2012, International journal of biochemistry and molecular biology.

[82]  P. Altevogt,et al.  Extracellular Vesicle-Mediated Transfer of Genetic Information between the Hematopoietic System and the Brain in Response to Inflammation , 2014, Journal of Neuroimmunology.

[83]  Timothy A. Miller,et al.  Method for widespread microRNA-155 inhibition prolongs survival in ALS-model mice. , 2013, Human molecular genetics.

[84]  Ke Li,et al.  Serum MicroRNA-21 as a Diagnostic Marker for Lung Carcinoma: A Systematic Review and Meta-Analysis , 2014, PloS one.

[85]  Clifford R Jack,et al.  Alzheimer disease: new concepts on its neurobiology and the clinical role imaging will play. , 2012, Radiology.

[86]  A. Quattrone,et al.  Genetic association of &agr;2-macroglobulin polymorphisms with AD in southern Italy , 2002, Neurology.

[87]  Y. Rabinowitz,et al.  C.57 C > T Mutation in MIR 184 is Responsible for Congenital Cataracts and Corneal Abnormalities in a Five-generation Family from Galicia, Spain , 2015, Ophthalmic genetics.

[88]  K. Czaplinski,et al.  Exportin 5 is a RanGTP-dependent dsRNA-binding protein that mediates nuclear export of pre-miRNAs. , 2004, RNA.

[89]  Abdelouahid Maghnouj,et al.  Identification of microRNAs in the cerebrospinal fluid as biomarker for the diagnosis of glioma. , 2012, Neuro-oncology.

[90]  A. Zepeda,et al.  Selective distribution and dynamic modulation of miRNAs in the synapse and its possible role in Alzheimer's Disease , 2014, Brain Research.

[91]  David S. Greenberg,et al.  Small RNA sequencing-microarray analyses in Parkinson leukocytes reveal deep brain stimulation-induced splicing changes that classify brain region transcriptomes , 2013, Front. Mol. Neurosci..

[92]  A. Fagan,et al.  Multimodal techniques for diagnosis and prognosis of Alzheimer's disease , 2009, Nature.

[93]  Lung-Ji Chang,et al.  Defining a new role of GW182 in maintaining miRNA stability , 2012, EMBO reports.

[94]  P. Falkai,et al.  microRNA‐34c is a novel target to treat dementias , 2011, The EMBO journal.

[95]  C. Willoughby,et al.  Mutation altering the miR-184 seed region causes familial keratoconus with cataract. , 2011, American journal of human genetics.

[96]  P. Nelson,et al.  Studying microRNAs in the brain: Technical lessons learned from the first ten years , 2012, Experimental Neurology.

[97]  J. Satoh,et al.  Aberrant microRNA expression in the brains of neurodegenerative diseases: miR‐29a decreased in Alzheimer disease brains targets neurone navigator 3 , 2010, Neuropathology and applied neurobiology.

[98]  Patrick Callier,et al.  Germline deletion of the miR-17-92 cluster causes growth and skeletal defects in humans , 2011, Nature Genetics.

[99]  Satoshi Shibata,et al.  A High-Resolution Structure of the Pre-microRNA Nuclear Export Machinery , 2009, Science.

[100]  David M. Rocke,et al.  Stability of miRNA in human urine supports its biomarker potential. , 2013, Biomarkers in medicine.

[101]  Zhongmin Liu,et al.  The Analysis of microRNA Expression Profiling for Coronary Artery Disease , 2013, Cardiology.

[102]  Mohan Liu,et al.  Mechanisms of microRNA-mediated gene regulation , 2009, Science in China Series C: Life Sciences.

[103]  C. Barbato,et al.  A lentiviral sponge for miR-101 regulates RanBP9 expression and amyloid precursor protein metabolism in hippocampal neurons , 2014, Front. Cell. Neurosci..

[104]  Zhenggang Jiang,et al.  Stability analysis of liver cancer-related microRNAs. , 2011, Acta biochimica et biophysica Sinica.

[105]  V. Álvarez,et al.  Profile of microRNAs in the plasma of Parkinson’s disease patients and healthy controls , 2013, Journal of Neurology.

[106]  J. Wood,et al.  The protein tyrosine kinase, fyn, in Alzheimer's disease pathology , 1993, Neuroreport.

[107]  Murray J. Cairns,et al.  Activity-associated miRNA are packaged in Map1b-enriched exosomes released from depolarized neurons , 2014, Nucleic acids research.

[108]  R. Shiekhattar,et al.  The Microprocessor complex mediates the genesis of microRNAs , 2004, Nature.

[109]  G. Ruvkun,et al.  A uniform system for microRNA annotation. , 2003, RNA.

[110]  M. Behlke,et al.  Chemical modification and design of anti-miRNA oligonucleotides , 2011, Gene Therapy.

[111]  W. Banks,et al.  Delivery across the blood-brain barrier of antisense directed against amyloid beta: reversal of learning and memory deficits in mice overexpressing amyloid precursor protein. , 2001, The Journal of pharmacology and experimental therapeutics.

[112]  Yuriy Gusev,et al.  Systematic evaluation of microRNA processing patterns in tissues, cell lines, and tumors. , 2007, RNA.

[113]  C. Burge,et al.  Conserved Seed Pairing, Often Flanked by Adenosines, Indicates that Thousands of Human Genes are MicroRNA Targets , 2005, Cell.

[114]  C. Marwick,et al.  First "antisense" drug will treat CMV retinitis. , 1998, JAMA.

[115]  P. Nelson,et al.  Technical variables in high-throughput miRNA expression profiling: much work remains to be done. , 2008, Biochimica et biophysica acta.

[116]  S. Halpain,et al.  The Protein Phosphatase PP2A/Bα Binds to the Microtubule-associated Proteins Tau and MAP2 at a Motif Also Recognized by the Kinase Fyn , 2012, The Journal of Biological Chemistry.

[117]  Q. Geng,et al.  Signature of Circulating MicroRNAs as Potential Biomarkers in Vulnerable Coronary Artery Disease , 2013, PloS one.

[118]  Joerg E Braun,et al.  The role of GW182 proteins in miRNA-mediated gene silencing. , 2013, Advances in experimental medicine and biology.

[119]  X. Piao,et al.  Effect of LNA- and OMeN-modified oligonucleotide probes on the stability and discrimination of mismatched base pairs of duplexes , 2012, Journal of Biosciences.

[120]  S. Wilton,et al.  RNA splicing manipulation: strategies to modify gene expression for a variety of therapeutic outcomes. , 2005, Current gene therapy.

[121]  F. Zindy,et al.  Silencing of the miR-17~92 cluster family inhibits medulloblastoma progression. , 2013, Cancer Research.

[122]  M. Nalls,et al.  Evidence for natural antisense transcript-mediated inhibition of microRNA function , 2010, Genome Biology.

[123]  E. Bronze-da-Rocha.  MicroRNAs Expression Profiles in Cardiovascular Diseases , 2014, BioMed research international.

[124]  M. Zavolan,et al.  Analysis of CDS-located miRNA target sites suggests that they can effectively inhibit translation , 2013, Genome research.

[125]  J. Steitz,et al.  Target mRNAs are repressed as efficiently by microRNA-binding sites in the 5′ UTR as in the 3′ UTR , 2007, Proceedings of the National Academy of Sciences.

[126]  S V Faraone,et al.  Genetics of Alzheimer's disease. , 1996, Journal of the Formosan Medical Association = Taiwan yi zhi.

[127]  E. Martin,et al.  Convergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease , 2011, PloS one.

[128]  G. Siegel,et al.  Antisense inhibition at the β-secretase-site of β-amyloid precursor protein reduces cerebral amyloid and acetyl cholinesterase activity in Tg2576 , 2007, Neuroscience.

[129]  Fei Li,et al.  Abundant conserved microRNA target sites in the 5′-untranslated region and coding sequence , 2009, Genetica.

[130]  C. Burge,et al.  Most mammalian mRNAs are conserved targets of microRNAs. , 2008, Genome research.